{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:58:32Z","timestamp":1793854712829,"version":"4.6.1"},"reference-count":351,"publisher":"American Chemical Society (ACS)","issue":"8","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"name":"CMRI"},{"name":"Peptide Synthesis Facility, Children's Medical Research Institute, Faculty of Medicine and Health, University of Sydney","award":["No PEP099"],"award-info":[{"award-number":["No PEP099"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Designing therapeutic payloads to deliver drug molecules to the desired target site is challenging and requires effective, stable, and safe delivery systems in cancer therapy. Lipid-based nanocarriers have gained substantial interest in preclinical and clinical studies in anticancer drugs, leveraging their potential for drug delivery over the last few decades. While lipid-based nanocarrier technology has achieved some commercial success in different therapeutics and vaccines, challenges persist in their design, development, and quality control in large-scale manufacturing, most notably a lack of robust and scalable lipid-based nanocarrier synthesis and formulation for chemotherapy. To overcome these limitations, it is crucial to understand the role of lipids and other constituents that are utilized in lipid-based nanocarrier synthesis. Along with the compositions of lipid-based nanocarriers, their preparation methods also play a critical role. The structural design of lipid-based nanocarriers aims to impart the desired physicochemical properties, stability, bioavailability, safety, and efficacy of the drug-loaded lipid-based nanocarriers. Initially, this review provides a brief overview of the classification of lipids and other essential components used in the preparation of lipid-based nanocarriers. We then examine critical formulation parameters, including composition ratios, physicochemical characteristics, and preparation methods. We also include the recent progress of cancer nanomedicine and clinical trials, regulatory approval, and future direction to improve the delivery efficiency of lipid-based nanocarriers in cancer nanomedicine. Finally, we summarize the formulation of five distinct types of lipid-based nanocarriers employed for anticancer drug delivery and draw a connection between these formulations and the development of mRNA-based lipid nanoparticles (LNPs).<\/jats:p>","DOI":"10.1021\/acsbiomaterials.6c00618","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T02:19:56Z","timestamp":1784081996000},"page":"3945-3984","source":"Crossref","is-referenced-by-count":2,"title":["Pharmaceutical Engineering of Lipid-Based Nanocarriers for Cancer Nanomedicines: From Doxorubicin to mRNA Platforms"],"prefix":"10.1021","volume":"12","author":[{"given":"Liam","family":"Gillman","sequence":"first","affiliation":[{"name":"University of Sydney , , , ,","place":["Westmead, New South Wales, Australia, 2145"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djordji","family":"Suleski","sequence":"additional","affiliation":[{"name":"University of Sydney , , , ,","place":["Westmead, New South Wales, Australia, 2145"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Graham","sequence":"additional","affiliation":[{"name":"University of Sydney , , , ,","place":["Westmead, New South Wales, Australia, 2145"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha L.","family":"Ginn","sequence":"additional","affiliation":[{"name":"The University of Sydney and The Sydney Children\u2019s Hospitals Network , , , ,","place":["Westmead, New South Wales, Australia, 2145"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3915-2709","authenticated-orcid":true,"given":"Md. Musfizur","family":"Hassan","sequence":"additional","affiliation":[{"name":"University of Sydney , , , ,","place":["Westmead, New South Wales, Australia, 2145"]},{"name":"University of New South Wales , , , ,","place":["Sydney, New South Wales, Australia, 2052"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"issue":"1","key":"2026081717150285700_cit1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"2026081717150285700_cit2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ajps.2013.07.010","article-title":"Development of liposomal formulations: From concept to clinical investigations","volume":"8","author":"Fan","year":"2013","journal-title":"Asian J. Pharm. Sci."},{"issue":"1","key":"2026081717150285700_cit3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ejpb.2004.06.009","article-title":"Development and characterization of a novel Cremophor\u00ae EL free liposome-based paclitaxel (LEP-ETU) formulation","volume":"59","author":"Zhang","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"8","key":"2026081717150285700_cit4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2023.06.025","article-title":"Lomustine\u2019s nanoemulsion as nose-to-brain drug delivery system for CNS tumor treatment","volume":"31","author":"Alaayedi","year":"2023","journal-title":"Saudi Pharm. J."},{"issue":"48","key":"2026081717150285700_cit5","doi-asserted-by":"publisher","first-page":"27826","DOI":"10.1039\/D5NR03373J","article-title":"Next-generation lipid nanocarriers for Parkinson's therapy: nose-to-brain innovations and clinical prospects","volume":"17","author":"Nabih","year":"2025","journal-title":"Nanoscale"},{"issue":"1","key":"2026081717150285700_cit6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-bioeng-071811-150124","article-title":"The effect of nanoparticle size, shape, and surface chemistry on biological systems","volume":"14","author":"Albanese","year":"2012","journal-title":"Annu. Rev. Biomed. Eng."},{"issue":"1","key":"2026081717150285700_cit7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1021\/nn900002m","article-title":"Impact of nanotechnology on drug delivery","volume":"3","author":"Farokhzad","year":"2009","journal-title":"ACS Nano"},{"issue":"12","key":"2026081717150285700_cit8","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"issue":"9","key":"2026081717150285700_cit9","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1002\/1097-0142(20010501)91:9&lt;1826::AID-CNCR1203&gt;3.0.CO;2-J","article-title":"Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: The relation between pharmacokinetic property and toxicity","volume":"91","author":"Hong","year":"2001","journal-title":"Cancer: Interdiscip. Int. J. Am. Cancer Soc."},{"issue":"27","key":"2026081717150285700_cit10","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"2026081717150285700_cit11","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"2026081717150285700_cit12","doi-asserted-by":"publisher","first-page":"A477","DOI":"10.1136\/jitc-2020-SITC2020.0798","article-title":"798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update","volume":"8","author":"Bauman","year":"2020","journal-title":"BMJ Spec. J."},{"key":"2026081717150285700_cit13","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1200\/JCO.2019.37.15_suppl.2523","article-title":"A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors","volume-title":"J. Clin. Oncol.","author":"Burris","year":"2019"},{"issue":"11","key":"2026081717150285700_cit14","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1172\/JCI134915","article-title":"mRNA vaccine\u2212induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer","volume":"130","author":"Cafri","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"4","key":"2026081717150285700_cit15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3390\/vaccines9040359","article-title":"Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines","volume":"9","author":"Thi","year":"2021","journal-title":"Vaccines"},{"key":"2026081717150285700_cit16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","article-title":"Self-assembled mRNA vaccines","volume":"170","author":"Kim","year":"2021","journal-title":"Adv. Drug Delivery Rev."},{"issue":"101","key":"2026081717150285700_cit17","doi-asserted-by":"publisher","DOI":"10.1098\/rsif.2014.0459","article-title":"Liposomes in tissue engineering and regenerative medicine","volume":"11","author":"Monteiro","year":"2014","journal-title":"J. R. Soc. Interface"},{"key":"2026081717150285700_cit18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1590\/S0100-879X1999000200006","article-title":"Liposomes: from biophysics to the design of peptide vaccines","volume":"32","author":"Frezard","year":"1999","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"6","key":"2026081717150285700_cit19","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1021\/acsmaterialsau.3c00032","article-title":"Lipid-Based Nanoparticles for Drug\/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development","volume":"3","author":"Mehta","year":"2023","journal-title":"ACS Mater. Au"},{"issue":"21","key":"2026081717150285700_cit20","doi-asserted-by":"publisher","first-page":"15764","DOI":"10.3390\/ijms242115764","article-title":"Lipid Nanoparticles: An Effective Tool to Improve the Bioavailability of Nutraceuticals","volume":"24","author":"Ashfaq","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"2026081717150285700_cit21","doi-asserted-by":"publisher","DOI":"10.1515\/dmpt-2018-0032","article-title":"Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles","volume":"34","author":"Alavi","year":"2019","journal-title":"Drug Metab. Pers. Ther."},{"issue":"2","key":"2026081717150285700_cit22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discovery"},{"key":"2026081717150285700_cit23","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115136","article-title":"Lipid nanoparticles for targeted delivery of anticancer therapeutics: Recent advances in development of siRNA and lipoprotein-mimicking nanocarriers","volume":"203","author":"Yaghmur","year":"2023","journal-title":"Adv. Drug Delivery Rev."},{"issue":"11","key":"2026081717150285700_cit24","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/s41563-021-01047-7","article-title":"Obstacles and opportunities in a forward vision for cancer nanomedicine","volume":"20","author":"de L\u00e1zaro","year":"2021","journal-title":"Nat. Mater."},{"key":"2026081717150285700_cit25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.nantod.2019.02.005","article-title":"Clinical cancer nanomedicine","volume":"25","author":"Wolfram","year":"2019","journal-title":"Nano Today"},{"issue":"11","key":"2026081717150285700_cit26","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.3390\/ma5112292","article-title":"Cell-Sized Liposomes and Droplets: Real-World Modeling of Living Cells","volume":"5","author":"Hamada","year":"2012","journal-title":"Materials"},{"issue":"5","key":"2026081717150285700_cit27","doi-asserted-by":"publisher","first-page":"660-IN10","DOI":"10.1016\/S0022-2836(64)80115-7","article-title":"Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope","volume":"8","author":"Bangham","year":"1964","journal-title":"J. Mol. Biol."},{"issue":"12","key":"2026081717150285700_cit28","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s12272-022-01418-x","article-title":"Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment","volume":"45","author":"Karim","year":"2022","journal-title":"Arch. Pharmacal Res."},{"issue":"11","key":"2026081717150285700_cit29","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.bbalip.2011.06.009","article-title":"Lipid classification, structures and tools","volume":"1811","author":"Fahy","year":"2011","journal-title":"Biochim. Biophys. Acta, Mol. Cell Biol. Lipids"},{"issue":"5","key":"2026081717150285700_cit30","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1194\/jlr.E400004-JLR200","article-title":"A comprehensive classification system for lipids","volume":"46","author":"Fahy","year":"2005","journal-title":"J. Lipid Res."},{"issue":"12","key":"2026081717150285700_cit31","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1194\/jlr.S120001025","article-title":"Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures","volume":"61","author":"Liebisch","year":"2020","journal-title":"J. Lipid Res."},{"key":"2026081717150285700_cit32","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.806713","article-title":"Fabrication and assessment of diosgenin encapsulated stearic acid solid lipid nanoparticles for its anticancer and antidepressant effects using in vitro and in vivo models","volume":"15","author":"Khan","year":"2022","journal-title":"Front. Neurosci."},{"key":"2026081717150285700_cit33","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2022.119401","article-title":"Chitosan-coated nanostructured lipid carriers for transdermal delivery of tetrahydrocurcumin for breast cancer therapy","volume":"288","author":"Truong","year":"2022","journal-title":"Carbohydr. Polym."},{"issue":"17","key":"2026081717150285700_cit34","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201902746","article-title":"MT1-MMP-Activated Liposomes to Improve Tumor Blood Perfusion and Drug Delivery for Enhanced Pancreatic Cancer Therapy","volume":"7","author":"Wei","year":"2020","journal-title":"Adv. Sci."},{"issue":"3","key":"2026081717150285700_cit35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrm.2017.107","article-title":"Sphingolipids and their metabolism in physiology and disease","volume":"19","author":"Hannun","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2026081717150285700_cit36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2026.114640","article-title":"A new type of lipid nanoparticles with sphingomyelin-induced active lipid raft structures for improved mRNA cellular uptake","volume":"391","author":"Ling","year":"2026","journal-title":"J. Controlled Release"},{"issue":"3-4","key":"2026081717150285700_cit37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/08982100500364131","article-title":"The effect of cholesterol in the liposome bilayer on the stabilization of incorporated retinol","volume":"15","author":"Lee","year":"2005","journal-title":"J. Liposome Res."},{"issue":"3","key":"2026081717150285700_cit38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2026.101009","article-title":"Prenols and prenoic acids in metabolism, disease, and aging","volume":"67","author":"Verdaguer","year":"2026","journal-title":"J. Lipid Res."},{"issue":"5","key":"2026081717150285700_cit39","doi-asserted-by":"publisher","first-page":"465","DOI":"10.4062\/biomolther.2021.107","article-title":"Bioactive Lipids and Their Derivatives in Biomedical Applications","volume":"29","author":"Park","year":"2021","journal-title":"Biomol. Ther."},{"issue":"11","key":"2026081717150285700_cit40","doi-asserted-by":"publisher","DOI":"10.1128\/aem.01603-24","article-title":"Targeted discovery of polyketides with antioxidant activity through integrated omics and cocultivation strategies","volume":"90","author":"Wang","year":"2024","journal-title":"Appl. Environ. Microbiol."},{"issue":"7-8","key":"2026081717150285700_cit41","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2533\/chimia.2019.581","article-title":"Derivation of Rapamycin: Adventures in Natural Product Chemistry","volume":"73","author":"Cottens","year":"2019","journal-title":"Chimia"},{"key":"2026081717150285700_cit42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.addr.2016.01.022","article-title":"The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery","volume":"99","author":"Cheng","year":"2016","journal-title":"Adv. Drug Delivery Rev."},{"issue":"4","key":"2026081717150285700_cit43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/cosmetics10040099","article-title":"Exploring Stearic-Acid-Based Nanoparticles for Skin Applications\u2014Focusing on Stability and Cosmetic Benefits","volume":"10","author":"Pereira-Leite","year":"2023","journal-title":"Cosmetics"},{"issue":"6197","key":"2026081717150285700_cit44","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1126\/science.1255288","article-title":"Polyunsaturated phospholipids facilitate membrane deformation and fission by endocytic proteins","volume":"345","author":"Pinot","year":"2014","journal-title":"Science"},{"issue":"1","key":"2026081717150285700_cit45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12645-019-0055-y","article-title":"Nanomedicine review: Clinical developments in liposomal applications","volume":"10","author":"Beltr\u00e1n-Gracia","year":"2019","journal-title":"Cancer Nanotechnol."},{"issue":"1","key":"2026081717150285700_cit46","doi-asserted-by":"publisher","first-page":"8607","DOI":"10.1038\/s41598-019-45185-0","article-title":"Enzymatic fluorometric assays for quantifying all major phospholipid classes in cells and intracellular organelles","volume":"9","author":"Tsuji","year":"2019","journal-title":"Sci. Rep."},{"key":"2026081717150285700_cit47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120571","article-title":"Design of liposomes as drug delivery system for therapeutic applications","volume":"601","author":"Guimar\u00e3es","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"5373","key":"2026081717150285700_cit48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.281.5373.78","article-title":"An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery","volume":"281","author":"Koltover","year":"1998","journal-title":"Science"},{"key":"2026081717150285700_cit49","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120574","article-title":"Exploring the impact of physicochemical properties of liposomal formulations on their in vivo fate","volume":"300","author":"Sheikholeslami","year":"2022","journal-title":"Life Sci."},{"issue":"10","key":"2026081717150285700_cit50","doi-asserted-by":"publisher","first-page":"17056","DOI":"10.1038\/natrevmats.2017.56","article-title":"Tools for translation: non-viral materials for therapeutic mRNA delivery","volume":"2","author":"Hajj","year":"2017","journal-title":"Nat. Rev. Mater."},{"issue":"1","key":"2026081717150285700_cit51","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202000099","article-title":"Nanoplatforms for mRNA therapeutics","volume":"4","author":"Meng","year":"2021","journal-title":"Adv. Ther."},{"issue":"10","key":"2026081717150285700_cit52","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1080\/17425247.2017.1276560","article-title":"Clinical experience with drug delivery systems as tools to decrease the toxicity of anticancer chemotherapeutic agents","volume":"14","author":"Maranh\u00e3o","year":"2017","journal-title":"Expert Opin. Drug Delivery"},{"issue":"1","key":"2026081717150285700_cit53","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41467-020-14527-2","article-title":"Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA","volume":"11","author":"Patel","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"2026081717150285700_cit54","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1450","article-title":"Stimuli-responsive liposomes for drug delivery","volume":"9","author":"Lee","year":"2017","journal-title":"Wiley Interdiscip. Rev.:Nanomed. Nanobiotechnol."},{"issue":"1","key":"2026081717150285700_cit55","doi-asserted-by":"publisher","first-page":"7545","DOI":"10.1038\/s41598-021-86860-5","article-title":"Ultrasound-triggered herceptin liposomes for breast cancer therapy","volume":"11","author":"Elamir","year":"2021","journal-title":"Sci. Rep."},{"key":"2026081717150285700_cit56","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114895","article-title":"Stealth and pseudo-stealth nanocarriers","volume":"198","author":"Wen","year":"2023","journal-title":"Adv. Drug Delivery Rev."},{"issue":"Pt A","key":"2026081717150285700_cit57","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Delivery Rev."},{"issue":"1","key":"2026081717150285700_cit58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0005-2736(91)90246-5","article-title":"Liposomes containing synthetic lipid derivatives of poly (ethylene glycol) show prolonged circulation half-lives in vivo","volume":"1066","author":"Allen","year":"1991","journal-title":"Biochim. Biophys. Acta, Biomembr."},{"issue":"3","key":"2026081717150285700_cit59","first-page":"297","article-title":"Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential","volume":"1","author":"Laura Immordino","year":"2006","journal-title":"Int. J. Nanomed."},{"issue":"2","key":"2026081717150285700_cit60","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1021\/mp500400k","article-title":"Real time measurement of PEG shedding from lipid nanoparticles in serum via NMR spectroscopy","volume":"12","author":"Wilson","year":"2015","journal-title":"Mol. Pharmaceutics"},{"issue":"20","key":"2026081717150285700_cit61","doi-asserted-by":"publisher","first-page":"10832","DOI":"10.1039\/C6NR02174C","article-title":"\u201cSheddable\u201d PEG-lipid to balance the contradiction of PEGylation between long circulation and poor uptake","volume":"8","author":"Zhao","year":"2016","journal-title":"Nanoscale"},{"key":"2026081717150285700_cit62","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.66","article-title":"Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles","volume":"2","author":"Mui","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"10","key":"2026081717150285700_cit63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241006","article-title":"The effects of PEGylation on LNP based mRNA delivery to the eye","volume":"15","author":"Ryals","year":"2020","journal-title":"PLoS One"},{"issue":"10","key":"2026081717150285700_cit64","doi-asserted-by":"publisher","first-page":"5304","DOI":"10.1021\/nl302638g","article-title":"PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics","volume":"12","author":"Perry","year":"2012","journal-title":"Nano Lett."},{"key":"2026081717150285700_cit65","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1039\/c3fd00057e","article-title":"Liposome and protein based stealth nanoparticles","volume":"166","author":"Nogueira","year":"2013","journal-title":"Faraday Discuss."},{"key":"2026081717150285700_cit66","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1208\/s12248-017-0049-9","article-title":"Liposomal drug product development and quality: current US experience and perspective","volume":"19","author":"Kapoor","year":"2017","journal-title":"AAPS J."},{"key":"2026081717150285700_cit67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2018.02.040","article-title":"Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities","volume":"277","author":"Belfiore","year":"2018","journal-title":"J. Controlled Release"},{"issue":"34","key":"2026081717150285700_cit68","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202402935","article-title":"Concepts and Approaches to Reduce or Avoid Protein Corona Formation on Nanoparticles: Challenges and Opportunities","volume":"11","author":"Barz","year":"2024","journal-title":"Adv. Sci."},{"issue":"2","key":"2026081717150285700_cit69","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/pharmaceutics10020057","article-title":"Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems","volume":"10","author":"Danaei","year":"2018","journal-title":"Pharmaceutics"},{"issue":"7","key":"2026081717150285700_cit70","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.3390\/molecules27072202","article-title":"Optimization of the Conditions of Solid Lipid Nanoparticles (SLN) Synthesis","volume":"27","author":"Musielak","year":"2022","journal-title":"Molecules"},{"issue":"11","key":"2026081717150285700_cit71","doi-asserted-by":"publisher","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid Nanoparticles\u2014From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"issue":"7","key":"2026081717150285700_cit72","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s11434-016-1039-5","article-title":"Multi-drug loaded vitamin E-TPGS nanoparticles for synergistic drug delivery to overcome drug resistance in tumor treatment","volume":"61","author":"Liu","year":"2016","journal-title":"Sci. Bull."},{"issue":"1","key":"2026081717150285700_cit73","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.bcp.2014.02.003","article-title":"D-alpha-tocopheryl polyethylene glycol succinate (TPGS) induces cell cycle arrest and apoptosis selectively in Survivin-overexpressing breast cancer cells","volume":"89","author":"Neophytou","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"2026081717150285700_cit74","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ejpb.2020.07.022","article-title":"A liposome-micelle-hybrid (LMH) oral delivery system for poorly water-soluble drugs: Enhancing solubilisation and intestinal transport","volume":"154","author":"Romana","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"8","key":"2026081717150285700_cit75","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3390\/pharmaceutics13081291","article-title":"Polymeric lipid hybrid nanoparticles (plns) as emerging drug delivery platform\u2014A comprehensive review of their properties, preparation methods, and therapeutic applications","volume":"13","author":"Sivadasan","year":"2021","journal-title":"Pharmaceutics"},{"key":"2026081717150285700_cit76","doi-asserted-by":"publisher","DOI":"10.1590\/s2175-97902020000118973","article-title":"A nanoemulsion-based delivery system for imatinib and in vitro anticancer efficacy","volume":"56","author":"Karimi","year":"2020","journal-title":"Braz. J. Pharm. Sci."},{"key":"2026081717150285700_cit77","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2020.114774","article-title":"Design of absorption enhancer containing self-nanoemulsifying drug delivery system (SNEDDS) for curcumin improved anti-cancer activity and oral bioavailability","volume":"324","author":"Kanwal","year":"2021","journal-title":"J. Mol. Liq."},{"key":"2026081717150285700_cit78","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.colsurfb.2017.11.047","article-title":"In-vitro digestion of curcumin loaded chitosan-coated liposomes","volume":"168","author":"Cuomo","year":"2018","journal-title":"Colloids Surf., B"},{"key":"2026081717150285700_cit79","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.biomaterials.2019.01.019","article-title":"Hierarchically targetable polysaccharide-coated solid lipid nanoparticles as an oral chemo\/thermotherapy delivery system for local treatment of colon cancer","volume":"197","author":"Shen","year":"2019","journal-title":"Biomaterials"},{"key":"2026081717150285700_cit80","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.actbio.2020.12.024","article-title":"Preparation of cetyl palmitate-based PEGylated solid lipid nanoparticles by microfluidic technique","volume":"121","author":"Arduino","year":"2021","journal-title":"Acta Biomater."},{"issue":"12","key":"2026081717150285700_cit81","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.3390\/polym14122459","article-title":"Boosting the Anticancer Activity of Sunitinib Malate in Breast Cancer through Lipid Polymer Hybrid Nanoparticles Approach","volume":"14","author":"Ahmed","year":"2022","journal-title":"Polymers"},{"key":"2026081717150285700_cit82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119246","article-title":"Antitumor activity of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs): In vitro and in vivo","volume":"580","author":"Yalcin","year":"2020","journal-title":"Int. J. Pharm."},{"key":"2026081717150285700_cit83","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.carbpol.2016.11.072","article-title":"Physico-chemical characterization of succinyl chitosan-stabilized liposomes for the oral co-delivery of quercetin and resveratrol","volume":"157","author":"Caddeo","year":"2017","journal-title":"Carbohydr. Polym."},{"issue":"1","key":"2026081717150285700_cit84","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s11671-025-04375-8","article-title":"Mucoadhesive chitosan-coated boswellic acids nanoparticles as promising gastroprotective nanoagents via modulation of the RAS\/ERK signaling pathway","volume":"20","author":"Attia","year":"2025","journal-title":"Discover Nano"},{"issue":"8","key":"2026081717150285700_cit85","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.3390\/pharmaceutics15082082","article-title":"Comparative Studies of the Uptake and Internalization Pathways of Different Lipid Nano-Systems Intended for Brain Delivery","volume":"15","author":"Mihailova","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"2026081717150285700_cit86","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12951-024-02812-x","article-title":"Role of size, surface charge, and PEGylated lipids of lipid nanoparticles (LNPs) on intramuscular delivery of mRNA","volume":"22","author":"Kong","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"21","key":"2026081717150285700_cit87","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.2174\/138161210791920496","article-title":"Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects","volume":"16","author":"Yoo","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"5","key":"2026081717150285700_cit88","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1021\/acsami.5b10352","article-title":"Appropriate Size of Magnetic Nanoparticles for Various Bioapplications in Cancer Diagnostics and Therapy","volume":"8","author":"Guo","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"3","key":"2026081717150285700_cit89","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103505","article-title":"Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids","volume":"28","author":"Mendon\u00e7a","year":"2023","journal-title":"Drug Discovery Today"},{"issue":"3","key":"2026081717150285700_cit90","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1021\/mp300684a","article-title":"Size-dependent tumor penetration and in vivo efficacy of monodisperse drug-silica nanoconjugates","volume":"10","author":"Tang","year":"2013","journal-title":"Mol. Pharmacol."},{"issue":"30","key":"2026081717150285700_cit91","doi-asserted-by":"publisher","first-page":"14411","DOI":"10.1039\/C6NR04091H","article-title":"Ultra-small lipid\u2212polymer hybrid nanoparticles for tumor-penetrating drug delivery","volume":"8","author":"Dehaini","year":"2016","journal-title":"Nanoscale"},{"issue":"4","key":"2026081717150285700_cit92","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00280-020-04048-6","article-title":"Docetaxel-loaded ultrasmall nanostructured lipid carriers for cancer therapy: in vitro and in vivo evaluation","volume":"85","author":"Li","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2026081717150285700_cit93","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ejps.2018.02.024","article-title":"Modeling of ultra-small lipid nanoparticle surface charge for targeting glioblastoma","volume":"117","author":"Mendes","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"issue":"33","key":"2026081717150285700_cit94","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1002\/adma.201502486","article-title":"Ultrasmall Gold Nanorod Vesicles with Enhanced Tumor Accumulation and Fast Excretion from the Body for Cancer Therapy","volume":"27","author":"Song","year":"2015","journal-title":"Adv. Mater."},{"issue":"3","key":"2026081717150285700_cit95","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ejps.2012.12.006","article-title":"A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics","volume":"48","author":"Steichen","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"issue":"9","key":"2026081717150285700_cit96","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1021\/acs.langmuir.2c02949","article-title":"Colloidal Perspective on Targeted Drug Delivery to the Central Nervous System","volume":"39","author":"Wang","year":"2023","journal-title":"Langmuir"},{"issue":"7","key":"2026081717150285700_cit97","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1021\/nl204175t","article-title":"Shape matters: intravital microscopy reveals surprising geometrical dependence for nanoparticles in tumor models of extravasation","volume":"12","author":"Smith","year":"2012","journal-title":"Nano Lett."},{"issue":"1","key":"2026081717150285700_cit98","doi-asserted-by":"publisher","first-page":"16989","DOI":"10.1038\/s41598-020-73218-6","article-title":"Application of smart solid lipid nanoparticles to enhance the efficacy of 5-fluorouracil in the treatment of colorectal cancer","volume":"10","author":"Smith","year":"2020","journal-title":"Sci. Rep."},{"key":"2026081717150285700_cit99","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3389\/fphar.2020.00539","article-title":"Shape matters: Comprehensive analysis of star-shaped lipid nanoparticles","volume":"11","author":"Cao","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"12","key":"2026081717150285700_cit100","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3390\/pharmaceutics12121223","article-title":"Studies on the Effect of Oil and Surfactant on the Formation of Alginate-Based O\/W Lidocaine Nanocarriers Using Nanoemulsion Template","volume":"12","author":"Sarheed","year":"2020","journal-title":"Pharmaceutics"},{"key":"2026081717150285700_cit101","doi-asserted-by":"publisher","first-page":"756","DOI":"10.21577\/0100-4042.20170247","article-title":"Preparation and characterization of nanoemulsion containing a natural naphthoquinone","volume":"41","author":"Rodrigues","year":"2018","journal-title":"Quim. Nova"},{"issue":"8","key":"2026081717150285700_cit102","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1007\/s11095-014-1300-z","article-title":"Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells","volume":"31","author":"Tran","year":"2014","journal-title":"Pharm. Res."},{"key":"2026081717150285700_cit103","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.msec.2016.09.016","article-title":"Preferential binding of positive nanoparticles on cell membranes is due to electrostatic interactions: A too simplistic explanation that does not take into account the nanoparticle protein corona","volume":"70","author":"Forest","year":"2017","journal-title":"Mater. Sci. Eng."},{"issue":"9","key":"2026081717150285700_cit104","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"2026081717150285700_cit105","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.apsb.2021.03.033","article-title":"Influencing factors and strategies of enhancing nanoparticles into tumors in vivo","volume":"11","author":"Zhang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"2026081717150285700_cit106","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/ijc.11108","article-title":"Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels","volume":"105","author":"Krasnici","year":"2003","journal-title":"Int. J. Cancer"},{"issue":"23","key":"2026081717150285700_cit107","first-page":"6831","article-title":"Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors","volume":"62","author":"Campbell","year":"2002","journal-title":"Cancer Res."},{"issue":"3","key":"2026081717150285700_cit108","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/etc.2470","article-title":"Cellular uptake of nanoparticles as determined by particle properties, experimental conditions, and cell type","volume":"33","author":"Kettler","year":"2014","journal-title":"Environ. Toxicol. Chem."},{"issue":"1","key":"2026081717150285700_cit109","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s11671-018-2728-6","article-title":"Insight into cellular uptake and intracellular trafficking of nanoparticles","volume":"13","author":"Foroozandeh","year":"2018","journal-title":"Nanoscale Res. Lett."},{"issue":"1","key":"2026081717150285700_cit110","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40005-020-00504-w","article-title":"Physical properties of nanoparticles do matter","volume":"51","author":"Kiio","year":"2021","journal-title":"J. Pharm. Invest."},{"issue":"4","key":"2026081717150285700_cit111","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ajps.2020.07.005","article-title":"Size, shape, charge and \u201cstealthy\u201d surface: Carrier properties affect the drug circulation time in vivo","volume":"16","author":"Di","year":"2021","journal-title":"Asian J. Pharm. Sci."},{"key":"2026081717150285700_cit112","first-page":"1041","volume-title":"Handbook of Nanoparticles","author":"D\u00edaz-Torres","year":"2015"},{"issue":"17","key":"2026081717150285700_cit113","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1002\/smll.200900520","article-title":"A surface-charge study on cellular-uptake behavior of F3-peptide-conjugated iron oxide nanoparticles","volume":"5","author":"Zhang","year":"2009","journal-title":"Small"},{"issue":"5","key":"2026081717150285700_cit114","first-page":"194","article-title":"Melt-homogenized solid lipid nanoparticles stabilized by the nonionic surfactant tyloxapol. I. Preparation and particle size determination","volume":"3","author":"Siekmann","year":"1994","journal-title":"Pharm. Pharmacol. Lett."},{"issue":"11","key":"2026081717150285700_cit115","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41571-023-00811-9","article-title":"Targeting cancer with mRNA\u2212lipid nanoparticles: key considerations and future prospects","volume":"20","author":"Kon","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026081717150285700_cit116","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118224","article-title":"Nanotechnology-mediated precision drug delivery strategies for breast cancer treatment","volume":"188","author":"Maleki","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"11","key":"2026081717150285700_cit117","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1039\/d3bm00219e","article-title":"Administration methods of lipid-based nanoparticle delivery systems for cancer treatment","volume":"11","author":"Lu","year":"2023","journal-title":"Biomater. Sci."},{"issue":"2","key":"2026081717150285700_cit118","doi-asserted-by":"publisher","first-page":"307","DOI":"10.4155\/tde.10.20","article-title":"Advances in image-guided intratumoral drug delivery techniques","volume":"1","author":"Solorio","year":"2010","journal-title":"Ther. Delivery"},{"issue":"4","key":"2026081717150285700_cit119","doi-asserted-by":"publisher","first-page":"288","DOI":"10.4103\/1735-5362.235156","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages","volume":"13","author":"Ghasemiyeh","year":"2018","journal-title":"Res. Pharm. Sci."},{"issue":"1","key":"2026081717150285700_cit120","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/pharmaceutics16010007","article-title":"Nano-Drug Delivery Systems in Oral Cancer Therapy: Recent Developments and Prospective","volume":"16","author":"Zhang","year":"2023","journal-title":"Pharmaceutics"},{"issue":"7","key":"2026081717150285700_cit121","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202202400","article-title":"Advances in Lipid-Based Codelivery Systems for Cancer and Inflammatory Diseases","volume":"12","author":"Jogdeo","year":"2023","journal-title":"Adv. Healthcare Mater."},{"key":"2026081717150285700_cit122","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.670124","article-title":"Orally Administrable Therapeutic Nanoparticles for the Treatment of Colorectal Cancer","volume":"9","author":"Ying","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"2","key":"2026081717150285700_cit123","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3390\/ma15020682","article-title":"Synthesis and Potential Applications of Lipid Nanoparticles in Medicine","volume":"15","author":"Musielak","year":"2022","journal-title":"Materials"},{"key":"2026081717150285700_cit124","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.scp.2017.07.002","article-title":"Lipid nanoparticles: Different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery","volume":"6","author":"Ganesan","year":"2017","journal-title":"Sustainable Chem. Pharm."},{"issue":"11","key":"2026081717150285700_cit125","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1039\/c5sm02958a","article-title":"Nanoemulsions: formation, properties and applications","volume":"12","author":"Gupta","year":"2016","journal-title":"Soft Matter"},{"issue":"5","key":"2026081717150285700_cit126","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1517\/17425247.2012.673278","article-title":"Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery","volume":"9","author":"Battaglia","year":"2012","journal-title":"Expert Opin. Drug Delivery"},{"key":"2026081717150285700_cit127","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119167","article-title":"Antisolvent precipitation of lipid nanoparticles in microfluidic systems \u2212 A comparative study","volume":"579","author":"Riewe","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"10","key":"2026081717150285700_cit128","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1080\/17425247.2016.1193151","article-title":"Microfluidic nanoprecipitation systems for preparing pure drug or polymeric drug loaded nanoparticles: an overview","volume":"13","author":"Ding","year":"2016","journal-title":"Expert Opin. Drug Delivery"},{"key":"2026081717150285700_cit129","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120346","article-title":"LinTT1 peptide-functionalized liposomes for targeted breast cancer therapy","volume":"597","author":"d'Avanzo","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"7","key":"2026081717150285700_cit130","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1002\/jcb.29651","article-title":"Development of a novel liposomal nanoparticle formulation of cisplatin to breast cancer therapy","volume":"121","author":"Ghafari","year":"2020","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"2026081717150285700_cit131","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.memsci.2004.12.013","article-title":"Preparation of double emulsions by membrane emulsification\u2014a review","volume":"251","author":"van der Graaf","year":"2005","journal-title":"J. Membr. Sci."},{"issue":"2","key":"2026081717150285700_cit132","first-page":"104","article-title":"Investigations on solid lipid nanoparticles prepared by precipitation in o\/w emulsions","volume":"42","author":"Siekmann","year":"1996","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"4","key":"2026081717150285700_cit133","doi-asserted-by":"publisher","first-page":"539","DOI":"10.35333\/jrp.2020.202","article-title":"Formulation and pharmacokinetic evaluation of rifampicin solid lipid nanoparticles","volume":"24","author":"Gamal","year":"2020","journal-title":"J. Res. Pharm."},{"issue":"9","key":"2026081717150285700_cit134","doi-asserted-by":"publisher","DOI":"10.1111\/jfbc.13868","article-title":"Teucrium polium extract-loaded solid lipid nanoparticles: A design and in vitro anticancer study","volume":"45","author":"Roumi","year":"2021","journal-title":"J. Food Biochem."},{"issue":"18","key":"2026081717150285700_cit135","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.3390\/molecules26185510","article-title":"Lipid-Based Nanocarrier System for the Effective Delivery of Nutraceuticals","volume":"26","author":"Subramanian","year":"2021","journal-title":"Molecules"},{"issue":"12","key":"2026081717150285700_cit136","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s11095-020-02811-1","article-title":"Folate Modified Long Circulating Nano-Emulsion as a Promising Approach for Improving the Efficiency of Chemotherapy Drugs in Cancer Treatment","volume":"37","author":"Song","year":"2020","journal-title":"Pharm. Res."},{"key":"2026081717150285700_cit137","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2012.09.021","article-title":"Solid lipid nanoparticles: production, characterization and applications","volume":"64","author":"Mehnert","year":"2012","journal-title":"Adv. Drug Delivery Rev."},{"issue":"1","key":"2026081717150285700_cit138","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0168-3659(94)90047-7","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization","volume":"30","author":"Schwarz","year":"1994","journal-title":"J. Controlled Release"},{"issue":"01n02","key":"2026081717150285700_cit139","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1142\/S179398441000016X","article-title":"Lipid\u2212polymer hybrid nanoparticles: synthesis, characterization and applications","volume":"01","author":"Zhang","year":"2010","journal-title":"Nano Life"},{"key":"2026081717150285700_cit140","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpx.2019.100030","article-title":"Comparison of bulk and microfluidics methods for the formulation of poly-lactic-co-glycolic acid (PLGA) nanoparticles modified with cell-penetrating peptides of different architectures","volume":"1","author":"Streck","year":"2019","journal-title":"Int. J. Pharm.: X"},{"key":"2026081717150285700_cit141","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jcis.2020.11.070","article-title":"High throughput acoustic microfluidic mixer controls self-assembly of protein nanoparticles with tuneable sizes","volume":"585","author":"Pourabed","year":"2021","journal-title":"J. Colloid Interface Sci."},{"issue":"1","key":"2026081717150285700_cit142","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of Lipid Nanoparticles for RNA Delivery","volume":"55","author":"Eygeris","year":"2022","journal-title":"Acc. Chem. Res."},{"issue":"1","key":"2026081717150285700_cit143","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1903664","article-title":"Developments and opportunities in continuous biopharmaceutical manufacturing","volume":"13","author":"Khanal","year":"2021","journal-title":"MAbs"},{"key":"2026081717150285700_cit144","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/9781118971147.ch15","article-title":"ICH Q5E Comparability of Biotechnological\/Biological Products Subject to Changes in Their Manufacturing Processes: Summary and Analysis of ICH Q5E Guideline","volume-title":"ICH Qual. Guidel.","author":"Raghavan","year":"2017"},{"key":"2026081717150285700_cit145","article-title":"ICH guideline Q13 on continuous manufacturing of drug substances and drug products - Scientific guideline","year":"2023","journal-title":"European Medicines Agency"},{"key":"2026081717150285700_cit146","doi-asserted-by":"publisher","DOI":"10.1016\/j.onano.2023.100153","article-title":"A microfluidic application for mass production of drug-loaded polymeric microspheres for a long-acting injectable with IVL-DrugFluidic\u00ae, a novel microfluidic microsphere manufacturing platform technology","volume":"12","author":"Chon","year":"2023","journal-title":"OpenNano"},{"issue":"1","key":"2026081717150285700_cit147","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1021\/acsnano.4c12965","article-title":"Robust, Scalable Microfluidic Manufacturing of RNA\u2212Lipid Nanoparticles Using Immobilized Antifouling Lubricant Coating","volume":"19","author":"Hwang","year":"2025","journal-title":"ACS Nano"},{"issue":"9","key":"2026081717150285700_cit148","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3390\/mi10090592","article-title":"Scalable Production of Monodisperse Functional Microspheres by Multilayer Parallelization of High Aspect Ratio Microfluidic Channels","volume":"10","author":"Chung","year":"2019","journal-title":"Micromachines"},{"issue":"14","key":"2026081717150285700_cit149","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1039\/d3ma00021d","article-title":"Scalable production of microscopic particles for biological delivery","volume":"4","author":"Lin","year":"2023","journal-title":"Mater. Adv."},{"issue":"2","key":"2026081717150285700_cit150","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/biophysica6020019","article-title":"Precise Engineering of Lipid-Based Delivery Systems Using Microfluidics for Biomedical Applications","volume":"6","author":"Rachamala","year":"2026","journal-title":"Biophysica"},{"key":"2026081717150285700_cit151","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/10_2021_169","article-title":"Microfluidic Devices as Process Development Tools for Cellular Therapy Manufacturing","volume":"179","author":"Aranda Hernandez","year":"2022","journal-title":"Adv. Biochem. Eng. Biotechnol."},{"issue":"11","key":"2026081717150285700_cit152","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1039\/d3lc01097j","article-title":"Toward microfluidic continuous-flow and intelligent downstream processing of biopharmaceuticals","volume":"24","author":"Sharma","year":"2024","journal-title":"Lab Chip"},{"issue":"4","key":"2026081717150285700_cit153","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40268-020-00321-4","article-title":"Comparability Considerations and Challenges for Expedited Development Programs for Biological Products","volume":"20","author":"Schrieber","year":"2020","journal-title":"Drugs R&D"},{"issue":"3","key":"2026081717150285700_cit154","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1021\/acs.oprd.5c00309","article-title":"Insights into Flow and Continuous Systems in Pharmaceutical Manufacturing: Challenges and Opportunities","volume":"30","author":"Daly","year":"2026","journal-title":"Org. Process Res. Dev."},{"issue":"5412","key":"2026081717150285700_cit155","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/244170a0","article-title":"Enzyme-containing liposomes alleviate a model for storage disease","volume":"244","author":"Gregoriadis","year":"1973","journal-title":"Nature"},{"key":"2026081717150285700_cit156","first-page":"175","article-title":"Microemulsions in cosmetics","volume":"66","author":"Nakajima","year":"1997","journal-title":"Ind. Appl. Microemulsions"},{"key":"2026081717150285700_cit157","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1016\/s0169-409x(02)00118-7","article-title":"Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations","volume":"54","author":"M\u00fcller","year":"2002","journal-title":"Adv. Drug Delivery Rev."},{"issue":"3","key":"2026081717150285700_cit158","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2174\/157016311796799062","article-title":"20 years of lipid nanoparticles (SLN & NLC): present state of development & industrial applications","volume":"8","author":"H Muller","year":"2011","journal-title":"Curr. Drug Discovery Technol."},{"key":"2026081717150285700_cit159","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-3-662-47862-2_11","volume-title":"Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement: Nanocarriers","author":"M\u00fcller","year":"2016"},{"key":"2026081717150285700_cit160","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1007\/s11095-006-0282-x","article-title":"A new polymer\u2212lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells","volume":"23","author":"Wong","year":"2006","journal-title":"Pharm. Res."},{"issue":"3","key":"2026081717150285700_cit161","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jconrel.2006.09.007","article-title":"Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer","volume":"116","author":"Wong","year":"2006","journal-title":"J. Controlled Release"},{"key":"2026081717150285700_cit162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.fbio.2016.04.005","article-title":"Effect of composition, hydrogenation of phospholipids and lyophilization on the characteristics of eugenol-loaded liposomes prepared by ethanol injection method","volume":"15","author":"Sebaaly","year":"2016","journal-title":"Food Biosci."},{"key":"2026081717150285700_cit163","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00155","article-title":"The multirole of liposomes in therapy and prevention of infectious diseases","volume":"9","author":"Nisini","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"2026081717150285700_cit164","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ajps.2014.09.004","article-title":"A review on phospholipids and their main applications in drug delivery systems","volume":"10","author":"Li","year":"2015","journal-title":"Asian J. Pharm. Sci."},{"issue":"7","key":"2026081717150285700_cit165","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3390\/nano6070125","article-title":"Soft interaction in liposome nanocarriers for therapeutic drug delivery","volume":"6","author":"Lombardo","year":"2016","journal-title":"Nanomaterials"},{"issue":"10","key":"2026081717150285700_cit166","first-page":"4730","article-title":"Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers","volume":"43","author":"Gabizon","year":"1983","journal-title":"Cancer Res."},{"issue":"1","key":"2026081717150285700_cit167","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ijpharm.2010.10.007","article-title":"New chimeric advanced Drug Delivery nano Systems (chi-aDDnSs) as doxorubicin carriers","volume":"402","author":"Gardikis","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"4","key":"2026081717150285700_cit168","first-page":"987","article-title":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes","volume":"54","author":"Gabizon","year":"1994","journal-title":"Cancer Res."},{"issue":"11","key":"2026081717150285700_cit169","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.3390\/nano10112104","article-title":"Enhanced in vitro magnetic cell targeting of doxorubicin-loaded magnetic liposomes for localized cancer therapy","volume":"10","author":"Riva","year":"2020","journal-title":"Nanomaterials"},{"issue":"9","key":"2026081717150285700_cit170","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.apsb.2020.04.011","article-title":"Remote loading paclitaxel-doxorubicin prodrug into liposomes for cancer combination therapy","volume":"10","author":"Yu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"5_suppl","key":"2026081717150285700_cit171","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1177\/10600280940280S503","article-title":"Pharmacology and toxicology of Cremophor EL diluent","volume":"28","author":"Dorr","year":"1994","journal-title":"Ann. Pharmacother."},{"issue":"8","key":"2026081717150285700_cit172","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1054\/bjoc.2001.1723","article-title":"A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin","volume":"84","author":"Veal","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"8","key":"2026081717150285700_cit173","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1517\/13543780903114168","article-title":"Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin","volume":"18","author":"Boulikas","year":"2009","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"2","key":"2026081717150285700_cit174","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/pharmaceutics9020012","article-title":"Liposomal Formulations in Clinical Use: An Updated Review","volume":"9","author":"Bulbake","year":"2017","journal-title":"Pharmaceutics"},{"issue":"4","key":"2026081717150285700_cit175","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.bbadis.2018.08.025","article-title":"The role of mitochondrial cardiolipin in heart function and its implication in cardiac disease","volume":"1865","author":"Dudek","year":"2019","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"issue":"4","key":"2026081717150285700_cit176","first-page":"567","article-title":"Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation","volume":"2","author":"Rahman","year":"2007","journal-title":"Int. J. Nanomed."},{"issue":"2","key":"2026081717150285700_cit177","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11095-016-2072-4","article-title":"Electrosprayed Myocet-like Liposomes: An Alternative to Traditional Liposome Production","volume":"34","author":"Collier","year":"2017","journal-title":"Pharm. Res."},{"issue":"6","key":"2026081717150285700_cit178","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1081\/cnv-120025086","article-title":"A dose-escalating pilot study of sterically stabilized, pegylated liposomal doxorubicin (Lipo-Dox\u00ae) in patients with metastatic breast cancer","volume":"21","author":"Chao","year":"2003","journal-title":"Cancer Invest."},{"issue":"3","key":"2026081717150285700_cit179","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl (CAELYX\u2122\/Doxil\u00ae) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann. Oncol."},{"issue":"2","key":"2026081717150285700_cit180","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae\u2014the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Controlled Release"},{"issue":"1","key":"2026081717150285700_cit181","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0005-2760(92)90218-K","article-title":"Effects of sphingomyelin and phosphatidylcholine acyl chains on the clearance of triacylglycerol-rich lipoproteins from plasma. Studies with lipid emulsions in rats","volume":"1126","author":"Redgrave","year":"1992","journal-title":"Biochim. Biophys. Acta, Lipids Lipid Metab."},{"issue":"3","key":"2026081717150285700_cit182","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jconrel.2012.09.006","article-title":"Liposomal paclitaxel formulations","volume":"163","author":"Koudelka","year":"2012","journal-title":"J. Controlled Release"},{"key":"2026081717150285700_cit183","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jconrel.2022.03.049","article-title":"Targeted nanomedicine in cisplatin-based cancer therapeutics","volume":"345","author":"Han","year":"2022","journal-title":"J. Controlled Release"},{"issue":"3","key":"2026081717150285700_cit184","first-page":"256","article-title":"The relationship between drug carrying ability of liposomes and phosphatidylcholines","volume":"25","author":"Wang","year":"2008","journal-title":"FINE CHEMICALS-DALIAN"},{"key":"2026081717150285700_cit185","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.cis.2003.10.023","article-title":"Formation and stability of nano-emulsions","volume":"108\u2013109","author":"Tadros","year":"2004","journal-title":"Adv. Colloid Interface Sci."},{"key":"2026081717150285700_cit186","first-page":"175","article-title":"Industrial applications of microemulsions","volume":"66","author":"Nakajima","year":"1997","journal-title":"Surfactant Sci. Ser."},{"issue":"1\u20132","key":"2026081717150285700_cit187","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ijpharm.2004.05.016","article-title":"Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation","volume":"280","author":"Bouchemal","year":"2004","journal-title":"Int. J. Pharm."},{"key":"2026081717150285700_cit188","first-page":"1","volume-title":"Nanoparticles for biomedical applications","author":"Leon","year":"2020"},{"key":"2026081717150285700_cit189","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3389\/fsufs.2019.00095","article-title":"Nanoemulsions and their potential applications in food industry","volume":"3","author":"Aswathanarayan","year":"2019","journal-title":"Front. Sustainable Food Syst."},{"issue":"5","key":"2026081717150285700_cit190","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1248\/bpb.b17-00964","article-title":"Influence of polysorbate 60 on formulation properties and bioavailability of morin-loaded nanoemulsions with and without low-saponification-degree polyvinyl alcohol","volume":"41","author":"Ikeuchi-Takahashi","year":"2018","journal-title":"Biol. Pharm. Bull."},{"key":"2026081717150285700_cit191","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jfoodeng.2015.07.037","article-title":"Influence of surfactant and processing conditions in the stability of oil-in-water nanoemulsions","volume":"167","author":"Silva","year":"2015","journal-title":"J. Food Eng."},{"key":"2026081717150285700_cit192","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.partic.2021.05.009","article-title":"Nanoemulsions for drug delivery","volume":"64","author":"Wilson","year":"2022","journal-title":"Particuology"},{"key":"2026081717150285700_cit193","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jconrel.2015.12.016","article-title":"Drug delivery and drug targeting with parenteral lipid nanoemulsions\u2014A review","volume":"223","author":"H\u00f6rmann","year":"2016","journal-title":"J. Controlled Release"},{"issue":"23","key":"2026081717150285700_cit194","doi-asserted-by":"publisher","first-page":"12396","DOI":"10.1021\/jf202612b","article-title":"Nanoemulsions of Cancer Chemopreventive Agent Benzyl Isothiocyanate Display Enhanced Solubility, Dissolution, and Permeability","volume":"59","author":"Qhattal","year":"2011","journal-title":"J. Agric. Food Chem."},{"key":"2026081717150285700_cit195","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110936","article-title":"Enhanced antitumor efficacy of lapachol-loaded nanoemulsion in breast cancer tumor model","volume":"133","author":"Mendes Miranda","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"2026081717150285700_cit196","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103614","article-title":"Incorporation of topotecan into sesame oil - Nanoemulsion potentiates its cytotoxic effect in cancer cells","volume":"75","author":"Bayoumi","year":"2022","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"2026081717150285700_cit197","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfa.2020.125618","article-title":"Brucine PEGylated nanoemulsion: In vitro and in vivo evaluation","volume":"608","author":"Elsewedy","year":"2021","journal-title":"Colloids Surf., A"},{"key":"2026081717150285700_cit198","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.2147\/IJN.S385166","article-title":"A Novel Nanoemulsion Formula for an Improved Delivery of a Thalidomide Analogue to Triple-Negative Breast Cancer; Synthesis, Formulation, Characterization and Molecular Studies","volume":"18","author":"Tawfik","year":"2023","journal-title":"Int. J. Nanomed."},{"key":"2026081717150285700_cit199","doi-asserted-by":"publisher","DOI":"10.1016\/j.onano.2022.100066","article-title":"Preparation, stability and biological activity of essential oil-based nano emulsions: A comprehensive review","volume":"8","author":"Singh","year":"2022","journal-title":"OpenNano"},{"key":"2026081717150285700_cit200","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1007\/s11095-004-7671-9","article-title":"Oral absorption enhancement of cromolyn sodium through noncovalent complexation","volume":"21","author":"Ding","year":"2004","journal-title":"Pharm. Res."},{"issue":"3","key":"2026081717150285700_cit201","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ejps.2010.11.014","article-title":"Development and characterization of parenteral nanoemulsions containing thalidomide","volume":"42","author":"Ara\u00fajo","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"issue":"6","key":"2026081717150285700_cit202","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3390\/nano9060821","article-title":"Current Applications of Nanoemulsions in Cancer Therapeutics","volume":"9","author":"S\u00e1nchez-L\u00f3pez","year":"2019","journal-title":"Nanomaterials"},{"key":"2026081717150285700_cit203","doi-asserted-by":"publisher","DOI":"10.1016\/j.fhfh.2022.100078","article-title":"A low energy approach to develop nanoemulsion by combining pea protein and Tween 80 and its application for vitamin D delivery","volume":"2","author":"Walia","year":"2022","journal-title":"Food Hydrocolloids Health"},{"issue":"3","key":"2026081717150285700_cit204","doi-asserted-by":"publisher","first-page":"446","DOI":"10.34172\/apb.2023.056","article-title":"An Overview of Nanostructured Lipid Carriers and its Application in Drug Delivery through Different Routes","volume":"13","author":"Khan","year":"2023","journal-title":"Adv. Pharm. Bull."},{"issue":"45","key":"2026081717150285700_cit205","doi-asserted-by":"publisher","first-page":"26777","DOI":"10.1039\/d0ra03491f","article-title":"A brief review on solid lipid nanoparticles: Part and parcel of contemporary drug delivery systems","volume":"10","author":"Duan","year":"2020","journal-title":"RSC Adv."},{"issue":"3","key":"2026081717150285700_cit206","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3390\/nano10030510","article-title":"Rapid microwave-assisted cisplatin-loaded solid lipid nanoparticles: synthesis, characterization and anticancer study","volume":"10","author":"Aldawsari","year":"2020","journal-title":"Nanomaterials"},{"key":"2026081717150285700_cit207","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2019.115682","article-title":"Targeted delivery and apoptosis induction of trans-resveratrol-ferulic acid loaded chitosan coated folic acid conjugate solid lipid nanoparticles in colon cancer cells","volume":"231","author":"Kumar","year":"2020","journal-title":"Carbohydr. Polym."},{"key":"2026081717150285700_cit208","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2019.101374","article-title":"Cytotoxic effects of gemcitabine-loaded solid lipid nanoparticles in pancreatic cancer cells","volume":"55","author":"Affram","year":"2020","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"2026081717150285700_cit209","doi-asserted-by":"publisher","first-page":"5035","DOI":"10.2147\/IJN.S86053","article-title":"Ph-responsive therapeutic solid lipid nanoparticles for reducing P-glycoprotein-mediated drug efflux of multidrug resistant cancer cells","volume":"10","author":"Chen","year":"2015","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"2026081717150285700_cit210","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.3762\/bjnano.10.208","article-title":"BergaCare SmartLipids: commercial lipophilic active concentrates for improved performance of dermal products","volume":"10","author":"Olechowski","year":"2019","journal-title":"Beilstein J. Nanotechnol."},{"issue":"10","key":"2026081717150285700_cit211","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/antiox9100998","article-title":"Solid lipid nanoparticles as carriers of natural phenolic compounds","volume":"9","author":"Borges","year":"2020","journal-title":"Antioxidants"},{"issue":"9","key":"2026081717150285700_cit212","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jsps.2021.07.015","article-title":"Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies","volume":"29","author":"Elmowafy","year":"2021","journal-title":"Saudi Pharm. J."},{"issue":"6","key":"2026081717150285700_cit213","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3109\/02652048.2014.911374","article-title":"The effect of surfactant composition on the chemical and structural properties of nanostructured lipid carriers","volume":"31","author":"Karn-Orachai","year":"2014","journal-title":"J. Microencapsulation"},{"issue":"1","key":"2026081717150285700_cit214","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3109\/21691401.2014.909822","article-title":"Nanostructured lipid carriers and their current application in targeted drug delivery","volume":"44","author":"Jaiswal","year":"2016","journal-title":"Artif. Cells, Nanomed., Biotechnol."},{"key":"2026081717150285700_cit215","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119576","article-title":"Novel decorated nanostructured lipid carrier for simultaneous active targeting of three anti-cancer agents","volume":"279","author":"Mahoutforoush","year":"2021","journal-title":"Life Sci."},{"issue":"12","key":"2026081717150285700_cit216","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1248\/cpb.56.1645","article-title":"Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying","volume":"56","author":"Zhang","year":"2008","journal-title":"Chem. Pharm. Bull."},{"issue":"7","key":"2026081717150285700_cit217","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3390\/pharmaceutics13071086","article-title":"Preparation, characterization, and anti-cancer activity of nanostructured lipid carriers containing imatinib","volume":"13","author":"Makeen","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"2026081717150285700_cit218","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1080\/10717544.2020.1754526","article-title":"Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro","volume":"27","author":"Makeen","year":"2020","journal-title":"Drug Delivery"},{"issue":"47","key":"2026081717150285700_cit219","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6528\/abaf81","article-title":"Nanostructured lipid carrier potentiated oral delivery of raloxifene for breast cancer treatment","volume":"31","author":"Soni","year":"2020","journal-title":"Nanotechnology"},{"key":"2026081717150285700_cit220","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118924","article-title":"Poloxamer 407 based-nanoparticles for controlled release of methotrexate","volume":"575","author":"Moura","year":"2020","journal-title":"Int. J. Pharm."},{"key":"2026081717150285700_cit221","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.mimet.2019.03.017","article-title":"Lipid-polymer hybrid nanoparticles: Synthesis strategies and biomedical applications","volume":"160","author":"Dave","year":"2019","journal-title":"J. Microbiol. Methods"},{"key":"2026081717150285700_cit222","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.2147\/IJN.S198353","article-title":"Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives","volume":"14","author":"Mukherjee","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"2026081717150285700_cit223","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2147\/IJN.S286221","article-title":"Gene Therapy for Drug-Resistant Glioblastoma via Lipid-Polymer Hybrid Nanoparticles Combined with Focused Ultrasound","volume":"16","author":"Yang","year":"2021","journal-title":"Int. J. Nanomed."},{"issue":"2","key":"2026081717150285700_cit224","doi-asserted-by":"publisher","DOI":"10.1002\/anbr.202100109","article-title":"Lipid nanoparticles for drug delivery","volume":"2","author":"Xu","year":"2022","journal-title":"Adv. NanoBiomed Res."},{"issue":"3","key":"2026081717150285700_cit225","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers"},{"key":"2026081717150285700_cit226","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.932156","article-title":"A new core\u2212shell-type nanoparticle loaded with paclitaxel\/norcantharidin and modified with APRPG enhances anti-tumor effects in hepatocellular carcinoma","volume":"12","author":"Xie","year":"2022","journal-title":"Front. Oncol."},{"key":"2026081717150285700_cit227","doi-asserted-by":"publisher","DOI":"10.1093\/rb\/rbae036","article-title":"A lipid\/PLGA nanocomplex to reshape tumor immune microenvironment for colon cancer therapy","volume":"11","author":"Zhang","year":"2024","journal-title":"Regener. Biomater."},{"key":"2026081717150285700_cit228","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119275","article-title":"Microfluidic fabrication and characterization of Sorafenib-loaded lipid-polymer hybrid nanoparticles for controlled drug delivery","volume":"581","author":"Tahir","year":"2020","journal-title":"Int. J. Pharm."},{"key":"2026081717150285700_cit229","doi-asserted-by":"publisher","first-page":"8055","DOI":"10.2147\/OTT.S259428","article-title":"Doxorubicin and Edelfosine Combo-Loaded Lipid-Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma","volume":"13","author":"Yang","year":"2020","journal-title":"OncoTargets Ther."},{"issue":"7","key":"2026081717150285700_cit230","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.3390\/pharmaceutics15071886","article-title":"Liposome-Micelle-Hybrid (LMH) Carriers for Controlled Co-Delivery of 5-FU and Paclitaxel as Chemotherapeutics","volume":"15","author":"Hassan","year":"2023","journal-title":"Pharmaceutics"},{"issue":"7","key":"2026081717150285700_cit231","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1208\/s12249-022-02389-4","article-title":"Lipid-and TPGS-based core\u2212shell-type nanocapsules endowed with high paclitaxel loading and enhanced anticancer potential","volume":"23","author":"Katiyar","year":"2022","journal-title":"AAPS PharmSciTech"},{"issue":"19","key":"2026081717150285700_cit232","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.3390\/ijms20194706","article-title":"Soy lecithin-derived liposomal delivery systems: Surface modification and current applications","volume":"20","author":"Le","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"2026081717150285700_cit233","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.3390\/ijms24054333","article-title":"PLGA-Based Micro\/Nanoparticles: An Overview of Their Applications in Respiratory Diseases","volume":"24","author":"Guo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"32","key":"2026081717150285700_cit234","doi-asserted-by":"publisher","first-page":"18997","DOI":"10.1074\/jbc.270.32.18997","article-title":"Cellular and molecular barriers to gene transfer by a cationic lipid","volume":"270","author":"Zabner","year":"1995","journal-title":"J. Biol. Chem."},{"issue":"4","key":"2026081717150285700_cit235","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1016\/S0021-9258(17)41980-6","article-title":"Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations","volume":"269","author":"Felgner","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"2","key":"2026081717150285700_cit236","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0005-2736(94)90066-3","article-title":"DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action","volume":"1189","author":"Zhou","year":"1994","journal-title":"Biochim. Biophys. Acta, Biomembr."},{"issue":"2","key":"2026081717150285700_cit237","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/0005-2736(95)80016-9","article-title":"The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer","volume":"1235","author":"Farhood","year":"1995","journal-title":"Biochim. Biophys. Acta, Biomembr."},{"issue":"4","key":"2026081717150285700_cit238","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1039\/d0bm01609h","article-title":"Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomater. Sci."},{"issue":"7089","key":"2026081717150285700_cit239","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature04688","article-title":"RNAi-mediated gene silencing in non-human primates","volume":"441","author":"Zimmermann","year":"2006","journal-title":"Nature"},{"key":"2026081717150285700_cit240","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"581 JK Narayanannair, KG Rajeev, IM Hafez, A. Akinc, MA Maier, MA Tracy, PR Cullis, TD 582 Madden, M. Manoharan, MJ Hope, Maximizing the potency of siRNA lipid nanoparticles for hepatic 583 gene silencing in vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew. Chem., Int. Ed."},{"issue":"10","key":"2026081717150285700_cit241","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1080\/17425247.2022.2135502","article-title":"Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications","volume":"19","author":"Lopes","year":"2022","journal-title":"Expert Opin. Drug Delivery"},{"key":"2026081717150285700_cit242","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2026081717150285700_cit243","unstructured":"Du, S. M. A. X.\n          \n          Lipids and lipid nanoparticle formulations for delivery of nucleic acids. US Patent US10166298B2. 2019."},{"key":"2026081717150285700_cit244","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2021.100424","article-title":"Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs","volume":"41","author":"Suzuki","year":"2021","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"3","key":"2026081717150285700_cit245","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3390\/vaccines11030658","article-title":"Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines","volume":"11","author":"Swetha","year":"2023","journal-title":"Vaccines"},{"issue":"5","key":"2026081717150285700_cit246","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"2026081717150285700_cit247","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1039\/c9tb02700a","article-title":"Amphetamine decorated cationic lipid nanoparticles cross the blood-brain barrier: therapeutic promise for combating glioblastoma","volume":"8","author":"Saha","year":"2020","journal-title":"J. Mater. Chem. B"},{"issue":"10","key":"2026081717150285700_cit248","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.1021\/acs.nanolett.8b02179","article-title":"Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy","volume":"18","author":"Sayour","year":"2018","journal-title":"Nano Lett."},{"issue":"11","key":"2026081717150285700_cit249","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202100144","article-title":"Virus-Mimic mRNA Vaccine for Cancer Treatment","volume":"4","author":"Meng","year":"2021","journal-title":"Adv. Ther."},{"issue":"3","key":"2026081717150285700_cit250","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett."},{"issue":"8","key":"2026081717150285700_cit251","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.3390\/ph15081017","article-title":"mRNA-Loaded Lipid Nanoparticles Targeting Immune Cells in the Spleen for Use as Cancer Vaccines","volume":"15","author":"Shimosakai","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"10","key":"2026081717150285700_cit252","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1158\/0008-5472.CAN-23-2875","article-title":"Lipid-Encapsulated mRNAs Encoding Complex Fusion Proteins Potentiate Antitumor Immune Responses","volume":"84","author":"Shuptrine","year":"2024","journal-title":"Cancer Res."},{"issue":"10","key":"2026081717150285700_cit253","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials of mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol."},{"issue":"8","key":"2026081717150285700_cit254","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1384","article-title":"mRNA vaccine in cancer therapy: Current advance and future outlook","volume":"13","author":"Li","year":"2023","journal-title":"Clin. Transl. Med."},{"issue":"9","key":"2026081717150285700_cit255","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1021\/acs.molpharmaceut.0c00451","article-title":"Efficient Colorectal Cancer Gene Therapy with IL-15 mRNA Nanoformulation","volume":"17","author":"Lei","year":"2020","journal-title":"Mol. Pharmaceutics"},{"issue":"1","key":"2026081717150285700_cit256","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40580-023-00385-3","article-title":"Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy","volume":"10","author":"Han","year":"2023","journal-title":"Nano Convergence"},{"issue":"Suppl 2","key":"2026081717150285700_cit257","doi-asserted-by":"publisher","first-page":"A451","DOI":"10.1136\/jitc-2021-SITC2021.421","article-title":"421 A first-in-human (FIH) phase I\/IIa clinical trial assessing a ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT","volume":"9","author":"Linch","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"2026081717150285700_cit258","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100267","article-title":"155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent\/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT","volume":"16","author":"Klinghammer","year":"2022","journal-title":"Immunol.-Oncol. Technol."},{"key":"2026081717150285700_cit259","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9503","article-title":"Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201\/KEYNOTE-942 trial","volume":"41","author":"Khattak","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"12_Supplement","key":"2026081717150285700_cit260","doi-asserted-by":"publisher","first-page":"CT183","DOI":"10.1158\/1538-7445.AM2022-CT183","article-title":"Abstract CT183: First-in-human study of MEDI1191 (mRNA encoding IL-12) plus durvalumab in patients (pts) with advanced solid tumors","volume":"82","author":"Carneiro","year":"2022","journal-title":"Cancer Res."},{"issue":"2","key":"2026081717150285700_cit261","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101463","article-title":"Lipid nanoparticles: Composition, formulation, and application","volume":"33","author":"Xu","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2026081717150285700_cit262","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Delivery Rev."},{"key":"2026081717150285700_cit263","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.colsurfb.2014.09.029","article-title":"Liposomes as carriers of hydrophilic small molecule drugs: Strategies to enhance encapsulation and delivery","volume":"123","author":"Eloy","year":"2014","journal-title":"Colloids Surf., B"},{"issue":"2","key":"2026081717150285700_cit264","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/molecules23020288","article-title":"Liposomes: clinical applications and potential for image-guided drug delivery","volume":"23","author":"Lamichhane","year":"2018","journal-title":"Molecules"},{"key":"2026081717150285700_cit265","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113588","article-title":"TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65\/16)","volume":"201","author":"Colombo","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"2026081717150285700_cit266","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1200\/JCO.2020.38.15_suppl.309","article-title":"A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36\u03b3, for intratumoral (iTu) injection alone and in combination with durvalumab","volume-title":"J. Clin. Oncol.","author":"Patel","year":"2020"},{"issue":"7","key":"2026081717150285700_cit267","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3390\/pharmaceutics13071009","article-title":"Clinical Advances of siRNA-Based Nanotherapeutics for Cancer Treatment","volume":"13","author":"Hattab","year":"2021","journal-title":"Pharmaceutics"},{"key":"2026081717150285700_cit268","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/TCRM.S5688","article-title":"Review of mifamurtide in the treatment of patients with osteosarcoma","volume":"6","author":"Kager","year":"2010","journal-title":"Ther. Clin. Risk Manage."},{"issue":"2","key":"2026081717150285700_cit269","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0169-409X(96)00453-X","article-title":"The design and development of DaunoXome\u00ae for solid tumor targeting in vivo","volume":"24","author":"Forssen","year":"1997","journal-title":"Adv. Drug Delivery Rev."},{"key":"2026081717150285700_cit270","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2147\/OTT.S79089","article-title":"A tale of the two PEGylated liposomal doxorubicins","volume":"8","author":"Chou","year":"2015","journal-title":"OncoTargets Ther."},{"issue":"43","key":"2026081717150285700_cit271","doi-asserted-by":"publisher","first-page":"12234","DOI":"10.3748\/wjg.v21.i43.12234","article-title":"Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer","volume":"21","author":"Fujita","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"2026081717150285700_cit272","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.addr.2020.07.002","article-title":"Liposomes: Advancements and innovation in the manufacturing process","volume":"154","author":"Shah","year":"2020","journal-title":"Adv. Drug Delivery Rev."},{"issue":"6","key":"2026081717150285700_cit273","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1080\/10428190500052438","article-title":"The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia","volume":"46","author":"Fassas","year":"2005","journal-title":"Leuk. Lymphoma"},{"issue":"8","key":"2026081717150285700_cit274","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3390\/molecules27082466","article-title":"Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases","volume":"27","author":"Tsvetkova","year":"2022","journal-title":"Molecules"},{"key":"2026081717150285700_cit275","first-page":"NA-NA","article-title":"FDA Approves and Authorizes Updated COVID-19 Vaccines","author":"Whitacre","year":"2023","journal-title":"Infect. Control Today"},{"issue":"11","key":"2026081717150285700_cit276","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"31","key":"2026081717150285700_cit277","doi-asserted-by":"publisher","first-page":"11449","DOI":"10.1073\/pnas.1411393111","article-title":"Correlating animal and human phase Ia\/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA","volume":"111","author":"Zuckerman","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"2026081717150285700_cit278","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/jcph.1480","article-title":"Patisiran pharmacokinetics, pharmacodynamics, and exposure-response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"2026081717150285700_cit279","doi-asserted-by":"publisher","first-page":"11006","DOI":"10.1200\/jco.2015.33.15_suppl.11006","article-title":"Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors","volume":"33","author":"Tolcher","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"2026081717150285700_cit280","doi-asserted-by":"publisher","first-page":"9788","DOI":"10.1158\/0008-5472.CAN-08-2428","article-title":"Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression","volume":"68","author":"Aleku","year":"2008","journal-title":"Cancer Res."},{"issue":"7","key":"2026081717150285700_cit281","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"2026081717150285700_cit282","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/colloids7010015","article-title":"Dynamic Light Scattering: A Powerful Tool for In Situ Nanoparticle Sizing","volume":"7","author":"Jia","year":"2023","journal-title":"Colloids Interfaces"},{"key":"2026081717150285700_cit283","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ymeth.2020.05.001","article-title":"Biophysical analysis of lipidic nanoparticles","volume":"180","author":"Rozo","year":"2020","journal-title":"Methods"},{"issue":"27","key":"2026081717150285700_cit284","doi-asserted-by":"publisher","first-page":"12871","DOI":"10.1039\/C8NR02278J","article-title":"Characterization techniques for nanoparticles: comparison and complementarity upon studying nanoparticle properties","volume":"10","author":"Mourdikoudis","year":"2018","journal-title":"Nanoscale"},{"issue":"2","key":"2026081717150285700_cit285","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1017\/S1431927618000181","article-title":"On the Progress of Scanning Transmission Electron Microscopy (STEM) Imaging in a Scanning Electron Microscope","volume":"24","author":"Sun","year":"2018","journal-title":"Microsc. Microanal."},{"issue":"4","key":"2026081717150285700_cit286","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3390\/pharmaceutics13040549","article-title":"Challenges in the Physical Characterization of Lipid Nanoparticles","volume":"13","author":"Hallan","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"2026081717150285700_cit287","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0009-3084(93)90062-8","article-title":"The use of differential scanning calorimetry as a tool to characterize liposome preparations","volume":"64","author":"Biltonen","year":"1993","journal-title":"Chem. Phys. Lipids"},{"issue":"18","key":"2026081717150285700_cit288","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202203022","article-title":"The Effect of Cryoprotectants and Storage Conditions on the Transfection Efficiency, Stability, and Safety of Lipid-Based Nanoparticles for mRNA and DNA Delivery","volume":"12","author":"Kafetzis","year":"2023","journal-title":"Adv. Healthcare Mater."},{"issue":"1","key":"2026081717150285700_cit289","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41541-023-00732-9","article-title":"Lyophilization process optimization and molecular dynamics simulation of mRNA-LNPs for SARS-CoV-2 vaccine","volume":"8","author":"Li","year":"2023","journal-title":"npj Vaccines"},{"key":"2026081717150285700_cit290","article-title":"The Importance Of Primary And Secondary Drying And Their Impact On Lyophilization","author":"Desai","year":"2025","journal-title":"Pharmaceutical Online"},{"key":"2026081717150285700_cit291","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cryobiol.2020.08.012","article-title":"Review of non-permeating cryoprotectants as supplements for vitrification of mammalian tissues","volume":"96","author":"Yong","year":"2020","journal-title":"Cryobiology"},{"key":"2026081717150285700_cit292","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3389\/fbioe.2019.00424","article-title":"Protective effect of saccharides on freeze-dried liposomes encapsulating drugs","volume":"7","author":"Guimaraes","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"9","key":"2026081717150285700_cit293","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3390\/pharmaceutics12090892","article-title":"Selection of cryoprotectant in lyophilization of progesterone-loaded stearic acid solid lipid nanoparticles","volume":"12","author":"Amis","year":"2020","journal-title":"Pharmaceutics"},{"key":"2026081717150285700_cit294","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2147\/IJN.S123062","article-title":"Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization","author":"Ball","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"2026081717150285700_cit295","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.102510","article-title":"Effects of monoclonal antibody concentration and type of bulking agent on critical quality attributes of lyophilisates","volume":"63","author":"Bjelo\u0161evi\u0107","year":"2021","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"2","key":"2026081717150285700_cit296","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s11095-016-2078-y","article-title":"Effects of Excipient Interactions on the State of the Freeze-Concentrate and Protein Stability","volume":"34","author":"Jena","year":"2017","journal-title":"Pharm. Res."},{"issue":"2","key":"2026081717150285700_cit297","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.xphs.2024.11.017","article-title":"Molecular mechanisms for stabilizing biologics in the solid state","volume":"114","author":"Ling","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"2026081717150285700_cit298","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.egyr.2021.12.039","article-title":"Vaccine cold chain management and cold storage technology to address the challenges of vaccination programs","volume":"8","author":"Pambudi","year":"2022","journal-title":"Energy Rep."},{"issue":"11","key":"2026081717150285700_cit299","doi-asserted-by":"publisher","first-page":"5667","DOI":"10.1039\/D5NR05189D","article-title":"Engineered strategies for enhancing mRNA vaccine stability in delivery and storage","volume":"18","author":"Cerav","year":"2026","journal-title":"Nanoscale"},{"key":"2026081717150285700_cit300","doi-asserted-by":"crossref","DOI":"10.14229\/jadc.2023.06.19.001","article-title":"How Process Enabling Closed Systems Offer Maximum Safety in ADC Manufacturing","author":"Moloney","year":"2023","journal-title":"J. Antibody-Drug Conjugates"},{"issue":"10","key":"2026081717150285700_cit301","doi-asserted-by":"publisher","first-page":"835","DOI":"10.18609\/cgti.2017.083","article-title":"Delivering Cell Therapies to Patients: Clinical & Logistical Challenges Past, Present & Future","volume":"3 (","author":"Forte","year":"2017","journal-title":"Cell Gene Ther. Insights"},{"key":"2026081717150285700_cit302","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.foodhyd.2018.09.006","article-title":"Interaction of soybean protein isolate and phosphatidylcholine in nanoemulsions: A fluorescence analysis","volume":"87","author":"Li","year":"2019","journal-title":"Food Hydrocolloids"},{"issue":"1","key":"2026081717150285700_cit303","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2342592","article-title":"Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size","volume":"20","author":"Shi","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"issue":"1","key":"2026081717150285700_cit304","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0378-5173(95)04286-5","article-title":"Crystallization tendency and polymorphic transitions in triglyceride nanoparticles","volume":"129","author":"Bunjes","year":"1996","journal-title":"Int. J. Pharm."},{"issue":"19","key":"2026081717150285700_cit305","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.1039\/d5na00323g","article-title":"Antibody-functionalized lipid nanocarriers for RNA-based cancer gene therapy: advances and challenges in targeted delivery","volume":"7","author":"Nabih","year":"2025","journal-title":"Nanoscale Adv."},{"key":"2026081717150285700_cit306","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jconrel.2024.05.036","article-title":"EGFR-targeted ionizable lipid nanoparticles enhance in vivo mRNA delivery to the placenta","volume":"371","author":"Geisler","year":"2024","journal-title":"J. Controlled Release"},{"key":"2026081717150285700_cit307","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jconrel.2024.04.022","article-title":"Lipid nanoparticle-based strategies for extrahepatic delivery of nucleic acid therapies \u2212 challenges and opportunities","volume":"370","author":"Simonsen","year":"2024","journal-title":"J. Controlled Release"},{"key":"2026081717150285700_cit308","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtadv.2022.100299","article-title":"Fabrication of active targeting lipid nanoparticles: Challenges and perspectives","volume":"16","author":"Menon","year":"2022","journal-title":"Mater. Today Adv."},{"issue":"5","key":"2026081717150285700_cit309","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/cancers11050640","article-title":"Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems","volume":"11","author":"Yoo","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"2026081717150285700_cit310","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1021\/acs.molpharmaceut.3c00735","article-title":"Unleashing the Potential: Designing Antibody-Targeted Lipid Nanoparticles for Industrial Applications with CMC Considerations and Clinical Outlook","volume":"21","author":"Wang","year":"2024","journal-title":"Mol. Pharmaceutics"},{"issue":"5","key":"2026081717150285700_cit311","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1208\/s12249-014-0143-6","article-title":"Nanoparticle ligand presentation for targeting solid tumors","volume":"15","author":"Duskey","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"2026081717150285700_cit312","doi-asserted-by":"publisher","DOI":"10.1016\/j.mattod.2025.12.034","article-title":"A material toolbox for engineering targeted lipid nanoparticles for RNA therapies","volume":"93","author":"Yoo","year":"2026","journal-title":"Mater. Today"},{"issue":"9","key":"2026081717150285700_cit313","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s41565-025-01954-9","article-title":"A versatile antibody capture system drives specific in vivo delivery of mRNA-loaded lipid nanoparticles","volume":"20","author":"Chen","year":"2025","journal-title":"Nat. Nanotechnol."},{"issue":"50","key":"2026081717150285700_cit314","doi-asserted-by":"publisher","first-page":"15343","DOI":"10.1021\/acs.langmuir.8b02946","article-title":"Distinction Between Active and Passive Targeting of Nanoparticles Dictate Their Overall Therapeutic Efficacy","volume":"34","author":"Clemons","year":"2018","journal-title":"Langmuir"},{"issue":"5","key":"2026081717150285700_cit315","doi-asserted-by":"publisher","first-page":"255","DOI":"10.52601\/bpr.2023.230022","article-title":"Surface engineering of lipid nanoparticles: targeted nucleic acid delivery and beyond","volume":"9","author":"Lin","year":"2023","journal-title":"Biophys. Rep."},{"key":"2026081717150285700_cit316","first-page":"12","article-title":"How Lipid Anchors Determine LNP Membrane Stability","year":"2026","journal-title":"Pure PEG"},{"issue":"10","key":"2026081717150285700_cit317","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3390\/vaccines12101148","article-title":"Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery","volume":"12","author":"Wang","year":"2024","journal-title":"Vaccines"},{"issue":"10","key":"2026081717150285700_cit318","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"6","key":"2026081717150285700_cit319","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.ymthe.2022.04.011","article-title":"Pro-inflammatory concerns with lipid nanoparticles","volume":"30","author":"Moghimi","year":"2022","journal-title":"Mol. Ther."},{"key":"2026081717150285700_cit320","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2026.101540","article-title":"Dissecting lipid nanoparticle adjuvanticity and reactogenicity to optimize vaccine formulations","volume":"76","author":"Hirai","year":"2026","journal-title":"Curr. Opin. Virol."},{"key":"2026081717150285700_cit321","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127892","article-title":"The relationship between the immunogenicity and reactogenicity of vaccines: A narrative review","volume":"68","author":"Gromer","year":"2025","journal-title":"Vaccine"},{"issue":"28","key":"2026081717150285700_cit322","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adw1731","article-title":"Enhanced immunocompatibility and hemocompatibility of nanomedicines across multiple species using complement pathway inhibitors","volume":"11","author":"Li","year":"2025","journal-title":"Sci. Adv."},{"key":"2026081717150285700_cit323","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.603039","article-title":"Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine","volume":"11","author":"La-Beck","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"2026081717150285700_cit324","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/vaccines13010014","article-title":"Regulating immune responses induced by PEGylated messenger RNA\u2212lipid nanoparticle vaccine","volume":"13","author":"Jo","year":"2024","journal-title":"Vaccines"},{"key":"2026081717150285700_cit325","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jconrel.2024.11.010","article-title":"Exploring the impact of commonly used ionizable and pegylated lipids on mRNA-LNPs: A combined in vitro and preclinical perspective","volume":"377","author":"Binici","year":"2025","journal-title":"J. Controlled Release"},{"issue":"36","key":"2026081717150285700_cit326","doi-asserted-by":"publisher","first-page":"24842","DOI":"10.1021\/acsnano.4c05088","article-title":"Lipid Nanoparticles Elicit Reactogenicity and Sickness Behavior in Mice Via Toll-Like Receptor 4 and Myeloid Differentiation Protein 88 Axis","volume":"18","author":"Korzun","year":"2024","journal-title":"ACS Nano"},{"key":"2026081717150285700_cit327","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1670350","article-title":"The mRNA component of LNP-mRNA vaccines triggers IFNAR-dependent immune activation which attenuates the adaptive immune response","volume":"16","author":"Bar-On","year":"2025","journal-title":"Front. Immunol."},{"key":"2026081717150285700_cit328","doi-asserted-by":"publisher","first-page":"2025-04","DOI":"10.1101\/2025.04.21.649878","article-title":"Systemic trafficking of mRNA lipid nanoparticle vaccine following intramuscular injection generates potent tissue-specific T cell response","volume-title":"bioRxiv","author":"Wei","year":"2025"},{"key":"2026081717150285700_cit329","doi-asserted-by":"publisher","first-page":"2024-08","DOI":"10.1101\/2024.08.02.606386","article-title":"Engineering ionizable lipids for rapid biodegradation balances mRNA vaccine efficacy and tolerability","author":"Couture-Sen\u00e9cal","year":"2024","journal-title":"bioRxiv"},{"key":"2026081717150285700_cit330","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpx.2026.100484","article-title":"Recent advances in lipid nanoparticles for cancer vaccine delivery: Challenges and future perspectives","volume":"11","author":"Hasan","year":"2026","journal-title":"Int. J. Pharm.: X"},{"issue":"8","key":"2026081717150285700_cit331","doi-asserted-by":"publisher","first-page":"7022","DOI":"10.1021\/acsnano.5c19036","article-title":"Comprehensive Engineering of Ionizable Lipid Nanoparticles and mRNA Elements for Next-Generation Vaccines","volume":"20","author":"Kim","year":"2026","journal-title":"ACS Nano"},{"issue":"45","key":"2026081717150285700_cit332","doi-asserted-by":"publisher","first-page":"41248","DOI":"10.1021\/jacs.5c16448","article-title":"Glycolipids Substitute PEG lipids in Lipid Nanoparticles for mRNA Delivery","volume":"147","author":"Jin","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"2026081717150285700_cit333","doi-asserted-by":"publisher","first-page":"2025-06","DOI":"10.1101\/2025.06.05.657891","article-title":"PEG-Free Tunable Poly(2-Oxazoline) Lipids Modulate LNP Biodistribution and Expression In Vivo after Intramuscular Administration","author":"Basham","year":"2025","journal-title":"bioRxiv"},{"issue":"2316","key":"2026081717150285700_cit334","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1098\/rsta.2024.0310","article-title":"Ionic liquids as alternative stabilizers for lipid nanoparticles used to deliver mRNA","author":"Yu","year":"2026","journal-title":"Philos. Trans. R. Soc., A"},{"issue":"2","key":"2026081717150285700_cit335","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1039\/d1bm01454d","article-title":"Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA)","volume":"10","author":"\u00c1lvarez-Benedicto","year":"2022","journal-title":"Biomater. Sci."},{"key":"2026081717150285700_cit336","first-page":"4","volume-title":"Phenolic Compounds","author":"Mohamed Hussein Hamdy","year":"2017"},{"issue":"6","key":"2026081717150285700_cit337","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1097\/01.sla.0000145964.08365.01","article-title":"Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?","volume":"240","author":"Adam","year":"2004","journal-title":"Ann. Surg."},{"issue":"5","key":"2026081717150285700_cit338","doi-asserted-by":"publisher","DOI":"10.19080\/oajt.2018.02.555600","article-title":"Chemotherapy treatment and strategy schemes: A review","volume":"2","author":"Alam","year":"2018","journal-title":"Open Access J. Toxicol."},{"key":"2026081717150285700_cit339","author":"Food, Administration, D","year":"2023","journal-title":"Comparability Protocols for Human Drugs and Biologics: Chemistry Manufacturing, and Controls Information"},{"key":"2026081717150285700_cit340","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/2051-1426-1-5","article-title":"Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation","volume":"1","author":"Vatsan","year":"2013","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"2026081717150285700_cit341","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.101170","article-title":"The comparability tales: A phase-appropriate roadmap for CGT drug product development","volume":"32","author":"Cl\u00e9ment","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2026081717150285700_cit342","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1190016","article-title":"Potency testing of cell and gene therapy products","volume":"10","author":"Salmikangas","year":"2023","journal-title":"Front. Med."},{"issue":"12","key":"2026081717150285700_cit343","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102422","article-title":"Current regulatory requirements for assessment of immunogenicity for gene therapy medicinal products","volume":"6","author":"Mann","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"6","key":"2026081717150285700_cit344","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1017\/cts.2020.493","article-title":"Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs","volume":"4","author":"Vandivort","year":"2020","journal-title":"J. Clin. Transl. Sci."},{"key":"2026081717150285700_cit345","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2147\/BTT.S124476","article-title":"Biosimilars and the extrapolation of indications for inflammatory conditions","volume":"11","author":"Tesser","year":"2017","journal-title":"Biologics"},{"issue":"17","key":"2026081717150285700_cit346","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1039\/d0bm00558d","article-title":"The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives","volume":"8","author":"Foulkes","year":"2020","journal-title":"Biomater. Sci."},{"key":"2026081717150285700_cit347","volume-title":"Handbook of Clinical Nanomedicine: Law, Business, Regulation, Safety, and Risk","year":"2016"},{"issue":"2","key":"2026081717150285700_cit348","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.35077","article-title":"Clinical Trials and Clinical Research: A Comprehensive Review","volume":"15","author":"Kandi","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"2026081717150285700_cit349","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1749-6632.1994.tb21701.x","article-title":"Cationic Liposomes for Direct Gene Transfer in Therapy of Cancer and Other Diseases","volume":"716","author":"Farhood","year":"1994","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"39","key":"2026081717150285700_cit350","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202204692","article-title":"mRNA Vaccines Against SARS-CoV-2 Variants Delivered by Lipid Nanoparticles Based on Novel Ionizable Lipids","volume":"32","author":"Chen","year":"2022","journal-title":"Adv. Funct. Mater."},{"key":"2026081717150285700_cit351","doi-asserted-by":"publisher","DOI":"10.1016\/j.ailsci.2026.100168","article-title":"Reprogramming cancer therapeutics through artificial intelligence-guided drug repurposing: Computational innovation, experimental validation, and translational challenges","volume":"9","author":"Fawzy","year":"2026","journal-title":"Artif. Intell. Life Sci."}],"container-title":["ACS Biomaterials Science &amp; Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsbiomaterials.6c00618","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/abseba\/article-pdf\/12\/8\/3945\/65946320\/ab-2026-00618j.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/abseba\/article-pdf\/12\/8\/3945\/65946320\/ab-2026-00618j.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:32:48Z","timestamp":1787002368000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/abseba\/article\/12\/8\/3945\/5210175\/Pharmaceutical-Engineering-of-Lipid-Based"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":351,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,7,14]]},"published-print":{"date-parts":[[2026,8,10]]}},"URL":"https:\/\/doi.org\/10.1021\/acsbiomaterials.6c00618","relation":{},"ISSN":["2373-9878"],"issn-type":[{"value":"2373-9878","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}